Cardiac Amyloidosis: Evolving Diagnosis and Management

Published: June 01, 2020

An illustration of a human torso highlighting the heart with heart vessels
  • This scientific statement is intended to inform clinical practice and facilitate management of transthyretin cardiac amyloidosis (ATTR-CM). The statement covers current diagnostic and treatment strategies while also identifying the lingering areas of uncertainty.
  • ATTR-CM is a restrictive cardiomyopathy that results from the extracellular myocardial deposition of amyloid fibrils composed of the protein transthyretin (TTR). 
  • Readily accessible, accurate, noninvasive diagnostic tests can facilitate ATTR-CM diagnosis, and therapies have emerged to slow the progression of symptoms and improve survival.